Healthtech company Sophia Genetics has announced it has raised $77 million to help accelerate its technologies into data-driven medicine.
Genomics
The latest funding round, led by Generation Investment Management, means that Sophia Genetics has now raised a total of $140 million. The company will use the funding to help it increase the number of global hospitals using its technology.
Sophia Genetics’ platform, Sophia AI, enables healthcare professionals to sift through complex genomic and radiomic data to more accurately diagnose and treat patients, both for oncology and hereditary disorders. The platform is currently used in over 850 hospitals and has helped support the diagnosis of over 300,000 patients.
“Since we founded the company, our goal has been to help make the global healthcare system more sustainable. By helping clinical researchers leverage their expertise and work together as community, patients all over the world can receive equal access to better care. Generation Investment Management and Sophia Genetics are guided by the same belief. With Generation’s support, we will enable the more rapid adoption of Data-Driven Medicine technology in healthcare for the benefit of patients worldwide,” commented Dr Jurgi Camblong, CEO and founder of Sophia Genetics.
“Generation are delighted to partner with Sophia Genetics. We believe that leveraging genetic sequencing and advanced digital analysis will enable a more sustainable healthcare system. Sophia Genetics is a leader in the preventive and personalised medicine revolution, enabling the development of targeted therapeutics, thereby vastly improving health outcomes” said Lilly Wollman, co-head of Generation’s Growth Equity team. “We admire Sophia Genetics not just for its differentiated analytics capability across genomic and radiomic data, but also for its exceptional team and culture”.